Zeiss Meditec Expands Intrabeam Uses
With approval received in the US, Europe and China, Carl Zeiss Meditec AG is expanding the applications of its Intrabeam radiotherapy system from primarily breast cancer to include additional cancer treatments.
The Zeiss Intrabeam intraoperative radiotherapy system. Courtesy of Business Wire.
Over the past 14 years, Intrabeam has been used to treat 8000 patients around the world, predominantly for breast cancer, Zeiss Meditec said. Unlike traditional radiotherapy, Intrabeam brings a low-energy x-ray source into direct contact with the tumor or tumor margin to irradiate the affected tissue more precisely, reducing irradiation to nearby healthy tissue and organs. Because it uses low x-ray energy (50 kV), the tool doesn't require complex radiation shielding and is suitable for mobile use, the company said.
"We now also offer patented radiation technology for patients with skin or gastrointestinal tumors, or with metastases in the spine area," said Dr. Ludwin Monz, president and CEO of Carl Zeiss Meditec AG.
For more information, visit:
www.meditec.zeiss.com
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024